Symbiogen Biotechnologies Profile
Key Indicators
- Authorised Capital ₹ 0.50 M
as on 04-12-2024
- Paid Up Capital ₹ 0.24 M
as on 04-12-2024
- Company Age 17 Year, 9 Months
- Last Filing with ROC 31 Mar 2023
- Revenue 37.47%
(FY 2021)
- Profit 49.98%
(FY 2021)
- Ebitda 22.64%
(FY 2021)
- Net Worth -13.44%
(FY 2021)
- Total Assets 3.95%
(FY 2021)
About Symbiogen Biotechnologies
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.50 M and a paid-up capital of Rs 0.24 M, as per Ministry of Corporate Affairs (MCA) records.
Satyamurty Gopal and Neela Saravanakumar serve as directors at the Company.
- CIN/LLPIN
U02411TN2007PTC063046
- Company No.
063046
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
09 Apr 2007
- Date of AGM
30 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Chennai
Industry
Company Details
- Location
Chennai, Tamil Nadu, India
- Telephone
- Email Address
- Website
-
- Social Media-
Who are the key members and board of directors at Symbiogen Biotechnologies?
Executive Team (1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Neela Saravanakumar  | Managing Director | 09-Apr-2007 | Current |
Board Members(1)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Satyamurty Gopal | Director | 09-Apr-2007 | Current |
Financial Performance of Symbiogen Biotechnologies.
Symbiogen Biotechnologies Private Limited, for the financial year ended 2021, experienced significant growth in revenue, with a 37.47% increase. The company also saw a substantial improvement in profitability, with a 49.98% increase in profit. The company's net worth observed a substantial decline by a decrease of 13.44%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metric |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Symbiogen Biotechnologies?
In 2021, Symbiogen Biotechnologies had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Scigenics Biotech Private LimitedActive 27 years 8 monthsSatyamurty Gopal and Neela Saravanakumar are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Symbiogen Biotechnologies?
Unlock and access historical data on people associated with Symbiogen Biotechnologies, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Symbiogen Biotechnologies, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Symbiogen Biotechnologies's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
